A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
暂无分享,去创建一个
R W Casey | M M Elhilali | J. Trachtenberg | M. Elhilali | L. Klotz | Y. Fradet | L H Klotz | J Trachtenberg | E. Schick | E W Ramsey | Y Fradet | J Barkin | R C Boake | G Beland | W L Orovan | E Schick | J. Barkin | R. Boake | G. Béland | E. Ramsey | W. Orovan | R. Casey
[1] H. Lepor,et al. The efficacy and safety of terazosin for the treatment of symptomatic BPH , 1991, The Prostate.
[2] S. Meretyk,et al. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. , 1978, British journal of urology.
[3] M. Soloway,et al. Efficacy of terazosin in patients with benign prostatic hyperplasia. , 1992, European urology.
[4] H. Lepor,et al. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH , 1992, The Prostate.
[5] P. G. Fabricius,et al. Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. , 1992, British journal of urology.
[6] G Jones,et al. A new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophy. , 1976, Transactions of the American Association of Genito-Urinary Surgeons.
[7] H. Lepor,et al. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. , 1992, The Journal of urology.
[8] H. Lepor,et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. , 1992, The Journal of urology.
[9] H. Lepor,et al. Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. , 1992, British journal of urology.
[10] N. Roos,et al. Use of claims data systems to evaluate health care outcomes. Mortality and reoperation following prostatectomy. , 1987, JAMA.
[11] M. Caine,et al. The use of alpha-adrenergic blockers in benign prostatic obstruction. , 1976, British journal of urology.
[12] D. McTavish,et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. , 1993, Drugs.
[13] U. Dunzendorfer,et al. Efficacy of once‐A‐day terazosin in benign prostatic hyperplasia: A randomized, double‐blind placebo‐controlled clinical trial , 1990, The Prostate. Supplement.
[14] E. Vaughan,et al. Medical management of benign prostatic hyperplasia. , 1990, Urology.
[15] A T Cockett,et al. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. , 1989, The Journal of urology.
[16] F. Di Silverio,et al. Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. , 1992 .
[17] R Guthrie. Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial. , 1994, The Journal of family practice.
[18] P. Walsh,et al. The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.
[19] S. Raz,et al. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. , 1975, British journal of urology.
[20] C P Chilton,et al. Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. , 1992, British journal of urology.
[21] R. Kirby,et al. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. , 1987, British journal of urology.
[22] K. Andersson,et al. Effects of prazosin in patients with benign prostatic obstruction. , 1983, The Journal of urology.
[23] H. Lepor,et al. The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. , 1990, The Journal of urology.
[24] M. Brawer,et al. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. , 1993, Archives of family medicine.
[25] A. Fitton,et al. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. , 1993, Drugs & aging.
[26] D. Gleason,et al. Effect of terazosin on urine storage and voiding in the aging male with prostatism , 1994, Neurourology and urodynamics.
[27] M. Barry,et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.